Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

virus at week 12 of narlaprevir treatment compared to 17 percent of patients at week 12 in the control arm.

Narlaprevir is a next-generation oral HCV protease inhibitor that achieves once-daily dosing through the use of low-dose ritonavir as a metabolic inhibitor. The NEXT-1 study evaluates 12 weeks of narlaprevir 200 mg or 400 mg once-daily or 100 mg twice daily with low-dose ritonavir (100 mg) in combination with PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (600-1400 mg daily), followed by PEGINTRON and REBETOL alone for an additional 12 or 36 weeks (24 or 48 weeks total). The study includes two treatment arms in which patients receive a 4-week lead-in of PEGINTRON and REBETOL prior to receiving narlaprevir 200 mg or 400 mg once-daily in the above regimen. All patients in the narlaprevir arms have completed narlaprevir dosing. The control arm is PEGINTRON and REBETOL alone for 48 weeks.

In this study, the rate of adverse events in the narlaprevir arms was similar to that in the peginterferon and ribavirin control arm, except for an increase in anemia (there were no discontinuations due to anemia) and an increase in low neutrophil counts (with no clinical sequelae). The most frequently seen adverse events up through 12 weeks of treatment were fatigue, nausea, flu-like illness, headache and insomnia. No increase in skin adverse events (rash or pruritus) beyond what was seen in the peginterferon and ribavirin control was observed.

For more information about ongoing narlaprevir clinical studies, please visit www.clinicaltrials.gov.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the lead
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... , NEW BRUNSWICK, N.J., Nov. 12 Senesco ... SNT ) announced today that Catherine Taylor, ... presenting pre-clinical stability and biological activity data on ... 2009 American Association for Cancer Research (AACR)-National Cancer ...
... Thoratec Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said today that it will ... HeartMate II Destination Therapy clinical trial that will be ... the American Heart Association(AHA) Scientific Sessions 2009. , The ...
Cached Medicine Technology:Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 3
(Date:7/10/2014)... the "Mississippi baby" an infant seemingly cured of HIV ... remission of HIV infection in The New England Journal ... after more than two years of not taking antiretroviral therapy ... and researchers involved in the case. , "Certainly, ... child, the medical staff involved in the child,s care, and ...
(Date:7/10/2014)... research at the University of Huddersfield could help to ... emulsion-based food products such as butter, mayonnaise, yoghurt ... gain an international profile for her work. , Katerina ... at the University and now she has embarked on ... Dr Vassilis Kontogiorgos, she is investigating the potential of ...
(Date:7/10/2014)... with localized prostate cancer were more likely to ... less effective treatments and survived for shorter times ... a UCLA study has found. , The negative ... such as bias against the mentally ill, depression,s ... lack of investment in his general health and ...
(Date:7/9/2014)... 2014) If you think winning is one of the ... again: Winning along with other mental bonuses ranked near the ... into one of 11 big fun factors, according to a ... important when it comes to the "fun" factor, very little ... goes into this elusive conceptuntil now. , The results of ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
Breaking Medicine News(10 mins):Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:World interest in research work on the benefits of the Okra plant 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2
... 25, 2010 (Toronto) A new study from The Centre ... accounts for 43% of all cigarettes consumed by Ontario high ... The study, published in the current edition of Tobacco ... and found that of high school daily smokers, 50% smoked ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Oct. 22 ... Staphylococcus aureus , or MRSA, a common bacterial infection acquired ... presented at the annual meeting of the Infectious Diseases Society ... of the people it infected within 30 days, the study ...
... DETROIT Patients admitted to the hospital for the ... a first line of defense with the potent antibiotic ... according to a Henry Ford Hospital study. For ... whether vancomycin or so-called B-lactam antibiotics like penicillin or ...
... Reporter , FRIDAY, Oct. 22 (HealthDay News) -- You might have seen ... an Iraq War vet with severe burns across much of his body ... his injuries. Martinez, 27, earned the right to play that role ... month into his first Iraq deployment as a real-life Army soldier, his ...
... School of Medicine, led by Lucila Ohno-Machado, MD, PhD, ... Department of Medicine, have received two federal grants totaling ... gather, analyze, use and share vast, ever-increasing amounts of ... over five years will create a national center for ...
... new cancer research being released at the American Society for ... 31 through November 4, 2010, in San Diego. For ... Napoli at nicolen@astro.org or Beth Bukata at ... 1:00 p.m. Eastern time. Adding radiation to hormone ...
Cached Medicine News:Health News:Contraband cigarettes main source of supply for Ontario youth 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 3Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 2Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 3Health News:UC San Diego receives 2 major biomedical informatics grants 2Health News:UC San Diego receives 2 major biomedical informatics grants 3Health News:UC San Diego receives 2 major biomedical informatics grants 4Health News:Practice-changing studies on how oncologists treat cancer to be presented at ASTRO Annual Meeting 2
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Angled tip with gently curved blade. Short hexagonal handle with polished finish. 0.5 mm x 15 mm tip....
0.5 mm short 90 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
Medicine Products: